Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age

NCT07284654 is registered in ClinicalTrials.gov with Vaxcyte, Inc. as lead sponsor.

NCT NCT07284654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age
Lead sponsor
Vaxcyte, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 1, 2025
Completion date
January 31, 2027
Enrollment
4,049 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal vaccines